{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:59:02Z","timestamp":1780581542939,"version":"3.54.1"},"reference-count":37,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Overactive bladder (OAB) is a common syndrome that can negatively affect patients\u2019 daily activities, sleep patterns, mental health, sexual function, and general health. In addition to reducing the frequency of attacks, treatment of OAB can be expected to improve the psychological and sexual health of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims:<\/jats:title>\n            <jats:p>To evaluate the effects of mirabegron used in the treatment of overactive bladder (OAB) on female sexual function (FSF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective study includes 48 sexually active women who were diagnosed with overactive bladder and treated with a daily oral dose of 50\u2009mg mirabegron between November 2021 and March 2022. The evaluation of FSF was conducted using female sexual function index (FSFI) along with urinary parameters before the start of the treatment and at the 6th week of the treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n              In the study, out of 48 participants, 40 (83.3%) were identified with the dry type and 8 (16.7%) with the wet type OAB. The median age when diagnosed was 43.5\u2009years. Although the decrease in the Overactive Bladder Questionnaire (OAB-V8) score did not reach statistical significance in the entire patient group after treatment (\n              <jats:italic>p<\/jats:italic>\n              \u2009=\u20090.058), a statistically significant decrease in the International Consultation on Incontinence Questionnaire\u2013Short Form (ICIQ-SF) score was detected in the wet type OAB group (\n              <jats:italic>p<\/jats:italic>\n              \u2009&lt;\u20090.001). During the assessment of sexual function, there was a statistically significant increase in the FSFI score, from 21.4 to 23.05, by the 6th week of treatment (\n              <jats:italic>p<\/jats:italic>\n              \u2009=\u20090.017). Specifically, the scores for desire, lubrication, and satisfaction showed a statistically significant post-treatment improvement (\n              <jats:italic>p<\/jats:italic>\n              \u2009&lt;\u20090.001,\n              <jats:italic>p<\/jats:italic>\n              \u2009=\u20090.049, and\n              <jats:italic>p<\/jats:italic>\n              \u2009=\u20090.035, respectively).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The study indicates that a 6-week regimen of a daily 50\u2009mg mirabegron dose enhanced sexual function in women. This beneficial impact of mirabegron on sexual health should be taken into account when selecting a treatment for OAB.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/03915603251316699","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:59:01Z","timestamp":1738562341000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Short-term effect of mirabegron on female sexual function in women with overactive bladder"],"prefix":"10.1177","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5758-5909","authenticated-orcid":false,"given":"Nihat","family":"Karabacak","sequence":"first","affiliation":[{"name":"Department of Urology, Gazi University, Yenimahalle, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-5727","authenticated-orcid":false,"given":"Murat Yavuz","family":"Koparal","sequence":"additional","affiliation":[{"name":"Department of Urology, Gazi University, Yenimahalle, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-1765","authenticated-orcid":false,"given":"Kadir \u015eerefhan","family":"Erten","sequence":"additional","affiliation":[{"name":"Department of Urology, Gazi University, Yenimahalle, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5450-5168","authenticated-orcid":false,"given":"Serhat","family":"\u00c7etin","sequence":"additional","affiliation":[{"name":"Department of Urology, Gazi University, Yenimahalle, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Onaran","sequence":"additional","affiliation":[{"name":"Department of Urology, Gazi University, Yenimahalle, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lker","family":"\u015een","sequence":"additional","affiliation":[{"name":"Department of Urology, Gazi University, Yenimahalle, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,2]]},"reference":[{"key":"e_1_3_2_2_2","author":"Abrams P","year":"2010","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of international continence society. In: Textbook of female urology and urogynecology. CRC Press, 2010, pp.1098\u2013108.","journal-title":"Textbook of female urology and urogynecology"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","DOI":"10.5213\/inj.2448002.001","article-title":"Pathophysiology of overactive bladder and pharmacologic treatments including \u03b23-adrenoceptor agonists-basic research perspectives","volume":"28","author":"Kwon J","year":"2024","unstructured":"Kwon J, Kim DY, Cho KJ, et al. Pathophysiology of overactive bladder and pharmacologic treatments including \u03b23-adrenoceptor agonists-basic research perspectives. Int Neurourol J 2024; 28(Suppl 1): S2.","journal-title":"Int Neurourol J"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025761"},{"key":"e_1_3_2_5_2","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams P","year":"2000","unstructured":"Abrams P, Kelleher C, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6(11 Suppl): S580\u2013S90.","journal-title":"Am J Manag Care"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80104-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40137-023-00374-9"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562872211039034"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.052"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.104"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287217702797"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2020.05.018"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.014"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/00926230590475206"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/009262300278597"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S269318"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20586"},{"issue":"9","key":"e_1_3_2_19_2","first-page":"3864","article-title":"Urodynamic parameter improvements after mirabegron vs. antimuscarinics agents in non-neurogenic overactive bladder: a systematic review and meta-analysis of treatment effect","volume":"27","author":"Warli SM","year":"2023","unstructured":"Warli SM, Firsty N, Natalia D, et al. Urodynamic parameter improvements after mirabegron vs. antimuscarinics agents in non-neurogenic overactive bladder: a systematic review and meta-analysis of treatment effect. Eur Rev Med Pharmacol Sci 2023; 27(9): 3864\u20133876.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11884-023-00704-8"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000508764"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2018.08.009"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-018-2030-7"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-007-0452-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2022.07.003"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.05.043"},{"key":"e_1_3_2_27_2","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","volume":"1","author":"Madhuvrata P","year":"2012","unstructured":"Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012; 1: CD005429.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0438-8"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-018-0377-9"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903103279"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.2987"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00976.x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702797"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13515"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0931347100"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01816.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003291.08","article-title":"MP45-08 a systematic review and meta-analysis of the effect of mirabegron on the sexual health of patients with overactive bladder (OAB) and sexual dysfunction","volume":"209","author":"Sakalis V","year":"2023","unstructured":"Sakalis V, Samarinas M, Giannitsas K, et al. MP45-08 a systematic review and meta-analysis of the effect of mirabegron on the sexual health of patients with overactive bladder (OAB) and sexual dysfunction. J Urol 2023; 209(Supplement 4): e624.","journal-title":"J Urol"},{"issue":"1","key":"e_1_3_2_38_2","article-title":"STOMp: sexual function trial of overactive bladder medication","volume":"11","author":"Polland A","year":"2023","unstructured":"Polland A, Hamner JJ, Arunachalam D, et al. STOMp: sexual function trial of overactive bladder medication. Sex Med 2023; 11(1): qfac001.","journal-title":"Sex Med"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251316699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603251316699","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251316699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:31:51Z","timestamp":1747197111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603251316699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/03915603251316699"],"URL":"https:\/\/doi.org\/10.1177\/03915603251316699","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,2]]}}}